Table 3. Differences of clinicopathological parameters according to the molecular types based on St. Gallen Consensus 2013.
| Total (n = 267) No. (%) | Luminal A (n = 58) No. (%) | Luminal B (n = 120) No. (%) | p-value* | HER2 (n = 39) No. (%) | TN (n = 50) No. (%) | p-value† | |
|---|---|---|---|---|---|---|---|
| Age (yr)‡ | 56.30 ± 10.61 | 56.15 ± 10.75 | 55.39 ± 10.63 | 0.984 | 54.23 ± 10.13 | 57.94 ± 10.96 | 0.511 |
| Tumor size (cm) | 0.009 | 0.003 | |||||
| ≤ 2.0 | 167 (62.5) | 47 (81.0) | 74 (61.7) | 22 (56.4) | 24 (48.0) | ||
| > 2.0 | 100 (37.5) | 11 (19.0) | 46 (38.3) | 17 (43.6) | 26 (52.0) | ||
| LN | 0.019 | 0.046 | |||||
| Negative | 160 (61.5) | 41 (75.9) | 67 (57.3) | 26 (66.7) | 26 (52.0) | ||
| Positive | 100 (38.5) | 13 (24.1) | 50 (42.7) | 13 (33.3) | 24 (48.0) | ||
| Grade | < 0.001 | < 0.001 | |||||
| Low | 50 (18.7) | 32 (55.2) | 18 (15.0) | 0 | 0 | ||
| Intermediate | 116 (43.4) | 23 (39.6) | 73 (60.8) | 10 (25.6) | 10 (20.0) | ||
| High | 101 (37.8) | 3 (5.2) | 29 (24.2) | 29 (74.4) | 40 (80.0) | ||
| p53 | 0.001 | < 0.001 | |||||
| Negative | 194 (72.7) | 58 (100.0) | 101 (84.2) | 17 (43.6) | 25 (50.0) | ||
| Positive | 66 (27.3) | 0 | 19 (15.8) | 22 (56.4) | 25 (50.0) | ||
| COX-2 | 0.288 | 0.002 | |||||
| Negative | 95 (35.6) | 13 (22.4) | 36 (30.0) | 16 (41.0) | 30 (60.0) | ||
| Positive | 172 (64.4) | 45 (77.6) | 84 (70.0) | 23 (59.0) | 20 (40.0) | ||
| Recurrence | 0.689 | 0.001 | |||||
| No | 230 (88.2) | 54 (94.7) | 109 (93.2) | 29 (74.4) | 38 (79.2) | ||
| Yes | 31 (11.8) | 3 (5.3) | 8 (6.8) | 10 (25.6) | 10 (20.8) | ||
| Death | 0.983 | 0.036 | |||||
| Alive | 256 (96.6) | 57 (98.3) | 117 (98.3) | 38 (97.4) | 44 (89.8) | ||
| Dead | 9 (3.4) | 1 (1.7) | 2 (1.7) | 1 (2.6) | 5 (10.2) |
HER2=human epidermal growth factor receptor 2; TN=triple-negative type; LN=lymph node; COX-2=cycloxygenase 2.
*Between the luminal A type vs. luminal B type; †Among the molecular types; ‡Mean±SD.